20 completed, 3 withdrawn, 2 active not recruiting, 2 recruiting. 29 Phase 1, 12 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 29 | Completed 20, Withdrawn 3, Active not recruiting 2, Recruiting 2, Terminated 1, Unknown 1 |
| Phase 2 | 12 | Completed 10, Recruiting 1, Withdrawn 1 |
Follow Malignant Pleural Mesothelioma: new trials by email Literature Review of Malignant Pleural Mesothelioma trials Research Report on Malignant Pleural Mesothelioma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors CTX131 - Clear Cell Renal Cell Carcinoma, Cervical Carcinoma | Phase 1 | Completed | CRISPR Therapeutics AG | 19 | 2023-03-13 | 2026-11-05 |
| Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma Dendritic cell vaccination, Atezolizumab, Platinum/pemetrexed based chemotherapy - Malignant Pleural Mesothelioma | Phase 1 / Phase 2 | Recruiting | University Hospital, Antwerp | 15 | 2023-02-24 | 2026-06-05 |
| AMT-151 in Patients With Selected Advanced Solid Tumours AMT-151 - Advanced Solid Tumor, Advanced Cancer | Phase 1 | Unknown | Multitude Therapeutics Inc. | 30 | 2023-01-25 | 2023-10-19 |
| Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma RSO-021 - Malignant Pleural Effusion, Malignant Pleural Mesothelioma | Phase 1 / Phase 2 | Completed | RS Oncology LLC | 50 | 2022-03-31 | 2026-07-24 |
| A Study of Pembrolizumab and Radiation Therapy in People With Mesothelioma Pembrolizumab, IMPRINT - Malignant Pleural Mesothelioma | Phase 1 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 7 | 2021-08-10 | 2026-03-12 |
| Pembrolizumab + Defactinib In Pleural Mesothelioma Pembrolizumab, Defactinib - Malignant Pleural Mesothelioma | Phase 1 | Withdrawn | Raphael Bueno, MD | 2020-09-01 | 2020-11-17 | |
| Poly-ICLC (Hiltonol®) Vaccine In Malignant Pleural Mesothelioma Safety, Expansion Cohort - Malignant Pleural Mesothelioma | Phase 1 | Completed | Oncovir, Inc. | 19 | 2020-08-19 | 2025-06-24 |
| A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma Nivolumab, Pemetrexed, Cisplatin or Carboplatin - Malignant Pleural Mesothelioma | Phase 1 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 22 | 2019-11-12 | 2026-09-11 |
| APG-2449 in Patients With Advanced Solid Tumors APG-2449 - Advanced Solid Cancer, Non Small Cell Lung Cancer | Phase 1 | Recruiting | Ascentage Pharma Group Inc. | 165 | 2019-05-27 | 2026-07-23 |
| Autologous Dendritic Cell Vaccination in Mesothelioma dendritic cell vaccination plus chemotherapy - Malignant Pleural Mesothelioma | Phase 1 / Phase 2 | Completed | University Hospital, Antwerp | 28 | 2017-10-03 | 2025-04-29 |
| Clinical Study of YS110 in Patients With Malignant Pleural Mesothelioma YS110 - Malignant Pleural Mesothelioma | Phase 1 / Phase 2 | Completed | Kissei Pharmaceutical Co., Ltd. | 40 | 2017-08-08 | 2020-09-25 |
| Concurrent Pemetrexed/Cisplatin With Pleural Intensity Modulated Radiation Therapy for Patients With Unresectable Malignant Pleural Mesothelioma Pemetrexed/Cisplatin, Pleural Intensity Modulated Radiation Therapy, MRI - Malignant Pleural Mesothelioma | Phase 1 | Withdrawn | Memorial Sloan Kettering Cancer Center | 2015-12-01 | 2016-12-07 | |
| A Study of BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural Mesothelioma BBI608, Pemetrexed, Cisplatin - Malignant Pleural Mesothelioma, Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | Completed | Sumitomo Pharma Co., Ltd. | 28 | 2015-02-01 | 2022-04-12 |
| Safety and Efficacy of Listeria in Combination With Chemotherapy as Front-line Treatment for Malignant Pleural Mesothelioma Immunotherapy plus chemotherapy, Immunotherapy with cyclophosphamide plus chemotherapy - Malignant Pleural Mesothelioma | Phase 1 | Completed | Aduro Biotech, Inc. | 60 | 2014-09-03 | 2020-09-30 |
| MesomiR 1: A Phase I Study of TargomiRs as 2nd or 3rd Line Treatment for Patients With Recurrent MPM and NSCLC TargomiRs - Malignant Pleural Mesothelioma, Non-Small Cell Lung Cancer | Phase 1 | Completed | Asbestos Diseases Research Foundation | 27 | 2014-09-01 | 2017-04-07 |
| Study of the Combination of Tivantinib Plus Pemetrexed and Carboplatin Tivantinib - Malignant Pleural Mesothelioma, Nonsquamous Nonsmall Cell Neoplasm of Lung | Phase 1 / Phase 2 | Completed | Armando Santoro, MD | 31 | 2013-01-01 | 2021-01-22 |
| Intracavitary Cisplatin-Fibrin Localized Chemotherapy After P/D or EPP for Malignant Pleural Mesothelioma intracavitary cisplatin-fibrin - Malignant Pleural Mesothelioma | Phase 1 / Phase 2 | Completed | University of Zurich | 47 | 2012-11-01 | 2021-09-29 |
| Intrapleural Administration of HSV1716 to Treat Patients With Malignant Pleural Mesothelioma. HSV1716 Intra-pleural delivery - Malignant Pleural Mesothelioma | Phase 1 / Phase 2 | Completed | Virttu Biologics Limited | 12 | 2012-10-01 | 2017-06-09 |
| Autologous Redirected RNA Meso-CIR T Cells Autologous T cells - Malignant Pleural Mesothelioma | Phase 1 | Completed | University of Pennsylvania | 18 | 2011-05-01 | 2017-09-19 |
| Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas Allogeneic Tumor Cell Vaccine (K562), Celecoxib, cyclophosphamide - Lung Cancer, Esophageal Cancer | Phase 1 | Terminated | National Cancer Institute (NCI) | 10 | 2010-12-07 | 2020-03-03 |
Showing 20 of 29. Sign in to see all of them.
Mesothelioma, Malignant (29) · Mesothelioma (6) · Carcinoma, Non-Small-Cell Lung (3) · Esophageal Neoplasms (3) · Neoplasms (3) · Carcinoma (2) · Ovarian Neoplasms (2) · Wilms Tumor (2) · Adenocarcinoma of Lung (1) · Carcinoma, Ovarian Epithelial (1) · Carcinoma, Renal Cell (1) · Disease Progression (1) · Endometrial Neoplasms (1) · Lung Neoplasms (1) · Pleural Effusion, Malignant (1)
Adenoma (29) · Lung Diseases (29) · Neoplasms by Histologic Type (29) · Neoplasms by Site (29) · Neoplasms, Glandular and Epithelial (29) · Neoplasms, Mesothelial (29) · Pleural Neoplasms (29) · Respiratory Tract Diseases (29) · Respiratory Tract Neoplasms (29) · Thoracic Neoplasms (29) · Lung Neoplasms (28) · Neoplasms (26) · Mesothelioma (23) · Female Urogenital Diseases (5) · Female Urogenital Diseases and Pregnancy Complications (5)
Cisplatin (9) · Pemetrexed (7) · Drug Therapy (3) · Cyclophosphamide (2) · pembrolizumab (2) · sodium thiosulfate (2) · ARQ 197 (1) · Amifostine (1) · Axitinib (1) · Carboplatin (1) · Cdc25C phosphatase (211-221) (1) · Celecoxib (1) · Cerebral Decortication (1) · Dasatinib (1) · Gemcitabine (1)
Memorial Sloan Kettering Cancer Center (3) · University Hospital, Antwerp (2) · Abramson Cancer Center at Penn Medicine (1) · Aduro Biotech, Inc. (1) · Armando Santoro, MD (1) · Asbestos Diseases Research Foundation (1) · Ascentage Pharma Group Inc. (1) · Brigham and Women's Hospital (1) · CRISPR Therapeutics AG (1) · CanBas Co. Ltd. (1) · Dana-Farber Cancer Institute (1) · Erasmus Medical Center (1) · Kissei Pharmaceutical Co., Ltd. (1) · M.D. Anderson Cancer Center (1) · Multitude Therapeutics Inc. (1)
United States (14) · Australia (2) · Belgium (2) · China (2) · Japan (2) · Netherlands (2) · United Kingdom (2) · Canada (1) · Italy (1) · Switzerland (1)
Raphael Bueno, MD (2) · Zwi N Berneman, MD, PhD (2) · Andrew Haas, MD, PhD (1) · Anne S. Tsao, MD (1) · Armando Santoro, MD (1) · Catherine Shannon (1) · Charles Simone, MD (1) · Daniel Sterman (1) · David J. Sugarbaker, MD (1) · David S Schrump, M.D. (1) · Dean Fennell (1) · Eva Lion, MSc, PhD (1) · Evelien LJ Smits, MSc, PhD (1) · Isabelle Opitz, Professor MD (1) · James Spicer, MD (1)
PMID 11487589, PMID 16554548, PMID 17295916, PMID 17395581, PMID 18797818, PMID 19360120, PMID 19564349, PMID 20167848, PMID 20549206, PMID 20615924, PMID 21135147, PMID 21149657, PMID 21467219, PMID 21632857, PMID 21642245, PMID 22065672, PMID 23032745, PMID 23248097, PMID 23785047, PMID 24148817, PMID 2418164, PMID 24366885, PMID 24445595, PMID 24484236, PMID 24487185, PMID 24739759, PMID 24777247, PMID 24777970, PMID 24852691, PMID 25281915, PMID 26968202, PMID 28298401, PMID 28870611, PMID 29975406, PMID 30962585, PMID 31263030, PMID 33450184, PMID 34187739, PMID 34312483, PMID 35820889, PMID 39008481, PMID 41146927, PMID 42448681, PMID 8727138
2009 (1), P01CA066726 (1)